List of patient-reported quality of life surveys

From Wikipedia, the free encyclopedia
Jump to: navigation, search

This page lists patient-reported quality of life surveys used in the field of medicine, pharmaceuticals, and other scientific trials. These surveys are patient-reported outcome measures, may be questionnaires or surveys, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.

List[edit]

  1. The Adult Asthma Quality of Life Questionnaire (AQLQ) was developed at McMaster University in Ontario, Canada and was published in 1992.[15] It has since been used as a comparison tool[16] as well as a tool in clinical trials.[17][18]
  2. The Asthma Life Impact Scale (ALIS) measure was developed in 2010 by Galen Research.[19] It has been translated into 16 languages.[20]
  1. The Parents’ Index of Quality of Life in Atopic Dermatitis (PiQOL-AD) measures the impact that atopic dermatitis has on quality of life, from the parents’ perspective.[21] It has 28 items and was developed simultaneously in the United Kingdom, The Netherlands, Germany, Italy, Spain, France and the United States.[22] It has been utilised in several research studies investigating the treatment of paediatric atopic dermatitis with pimecrolimus.[23][24][25] and also in a research study regarding health-related quality of life measurement in children in Ibero-American countries.[26]
  2. The Quality of Life Index for Atopic Dermatitis (QoLIAD) measures the impact that atopic dermatitis has on a given patient’s quality of life.[27] It is a 25 item questionnaire for patients over the age of 16.[28] The QoLIAD has also been utilized in studies looking into educational intervention,[29][30] topical corticosteroids[31] and pimecrolimus.[32]
  1. The Quality of Well-Being Scale (QWB) was developed in the 1970s, and a self-administered version called the QWB-SA was published in 1996.[59] The QWB has been used in studies investigating HIV patients[60][61] and musculoskeletal disease,[62] amongst others.
  2. The EuroQoL (EQ-5D) is a generalised health-related quality of life measure which was developed in 1991 by the EuroQol Group.[63] It has five standard dimensions and has been translated into over 60 languages.[64] The EuroQoL has been extensively used in clinical trials, investigating a range of topics including overactive bladder,[65] attention deficit hyperactivity disorder[66] and denosumab for osteoporosis.[67]
  3. The Nottingham Health Profile (NHP) is a general patient-reported outcome designed to measure a patient’s view of their own health status, in a number of areas.[68] It can be completed in 5 minutes.[69] It was developed in 1975 and current copyright belongs to Galen Research.[70] Clinical research studies where the NHP has been utilized include investigations into erythropoiesis-stimulating agents,[71] glucocorticoid replacement therapy[72] and transcutaneous electrical nerve stimulation for tinnitus.[73]
  4. The Short Form 36 (SF-36) Health Survey is a survey of general health developed by the RAND corporation.[74] It was designed for use in clinical practice, research, health policy evaluations and population surveys.[75] It has been used in numerous studies including ones investigating giardia intestinalis,[76] breast cancer survivors[77] and Parkinson’s disease.[78]
  5. The Sickness Impact Profile (SIP) was developed in 1997 by the Johns Hopkins University.[79] It consists of 136 items and has been adapted for strokes,[80] patients with ileal urinary diversions[81] and ex-ICU patients.[82]
  6. The Health Utilities Index measures health status, health-related quality of life and produces utility scores.[83] It was developed by Health Utilities Inc. in Canada.[84] It has been used in clinical studies investigating knee osteoarthritis,[85] urinary incontinence[86] and children who have been admitted to intensive care.[87]
  1. The Herpes Outbreak Impact Questionnaire (HOIQ) is designed to determine the impact of recurrent genital herpes outbreaks on a patient’s life.[88] Its efficacy has been tested in an Australian clinical trial.[89]
  2. The Herpes Symptom Checklist (HSC) was developed alongside the HOIQ in order to assess daily symptoms of genital herpes outbreaks.[90] It was also used in an Australian clinical trial which tested the effectiveness of famciclovir.[91]
  3. The Recurrent genital herpes quality of life measure (RGHQoL) was developed in 1998 by Galen Research in order to assess the impact recurrent genital herpes has on quality of life.[92] It has been used in clinical trials investigating famciclovir,[93] suppressive antiviral therapy[94] and patient perspectives and quality of life.[95][96]

References[edit]

  1. ^ "ACQLI". Galen-Research.com. Galen Research. Retrieved 11 November 2013. 
  2. ^ ClinicalTrials.gov NCT00428090 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
  3. ^ ClinicalTrials.gov NCT00348309 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)
  4. ^ ClinicalTrials.gov NCT00348140 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)
  5. ^ Levy, Karen; Lanctôt, Krista L.; Farber, Shale B.; Li, Abby; Herrmann, Nathan (2012). "Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimerʼs Disease Relieve Caregiver Burden?". Drugs & Aging 29 (3): 167. doi:10.2165/11599140-000000000-00000. 
  6. ^ Spertus, J.A.; Winder, J.A.; Dewhurst, T.A.; Deyo, R.A.; Prodzinski, J.; McDonell, M.; Fihn, S.D. (1995). "Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease". Journal of the American College of Cardiology 25 (2): 333–341. doi:10.1016/0735-1097(94)00397-9. PMID 7829785. Retrieved 27 November 2013. 
  7. ^ Jitta, D.J.; DeJongste, M.J.; Kliphuis, C.M.; Staal, M.J. (2011). "Multimorbidity, the predominant predictor of quality-of-life, following successful spinal cord stimulation for angina pectoris.". Neuromodulation 14 (1): 13–18. doi:10.1111/j.1525-1403.2010.00321.x. PMID 21992156. Retrieved 27 November 2013. 
  8. ^ Villano, A; Di Franco, A.; Nerla, R.; Sestito, A.; Tarzia, P.; Lamendola, P.; Di Monaco, A.; Sarullo, F.M.; Lanza, G.A.; Crea, F. (2013). "Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.". The American Journal of Cardiology 112 (1): 8–13. doi:10.1016/j.amjcard.2013.02.045. PMID 23558043. Retrieved 27 November 2013. 
  9. ^ Andrelle, P.; Ekre, O.; Grip, L.; Wahrborg, P.; Albertsson, P.; Eliasson, T.; Jeppsson, A.; Mannheimer, C. (2011). "Fatality, morbidity and quality of life in patients with refractory angina pectoris.". International Journal of Cardiology 147 (3): 377–382. doi:10.1016/j.ijcard.2009.09.538. PMID 19880202. Retrieved 27 November 2013. 
  10. ^ Doward, L C; Spoorenberg, A; Cook, SA; Whalley, D; Helliwell, PS; Kay, LJ; McKenna, SP; Tennant, A; Van Der Heijde, D; Chamberlain, MA (2003). "Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis". Annals of the Rheumatic Diseases 62 (1): 20–6. doi:10.1136/ard.62.1.20. PMC 1754293. PMID 12480664. 
  11. ^ Van Der Heijde, Désirée M; Revicki, Dennis A; Gooch, Katherine L; Wong, Robert L; Kupper, Hartmut; Harnam, Neesha; Thompson, Chris; Sieper, Joachim (2009). "Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis". Arthritis Research & Therapy 11 (4): R124. doi:10.1186/ar2790. 
  12. ^ Davis, John C.; Revicki, Dennis; Van Der Heijde, Désirée M. F.; Rentz, Anne M.; Wong, Robert L.; Kupper, Hartmut; Luo, Michelle P. (2007). "Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study". Arthritis & Rheumatism 57 (6): 1050. doi:10.1002/art.22887. 
  13. ^ Marzo-Ortega, Helena; McGonagle, Dennis; O'Connor, Philip; Emery, Paul (2001). "Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study". Arthritis & Rheumatism 44 (9): 2112. doi:10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. 
  14. ^ Marzo-Ortega, H; McGonagle, D; Haugeberg, G; Green, MJ; Stewart, SP; Emery, P (2003). "Bone mineral density improvement in spondyloarthropathy after treatment with etanercept". Annals of the Rheumatic Diseases 62 (10): 1020–1. doi:10.1136/ard.62.10.1020. PMC 1754338. PMID 12972490. 
  15. ^ Juniper, E.F.; Guyatt, G.H.; Epstein, R.S.; Ferrie, P.J.; Jaeschke, R.; Hiller, T.K. (1992). "Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials". Thorax 47 (2): 76–83. doi:10.1136/thx.47.2.76. PMC 463574. PMID 1549827. Retrieved 25 November 2013. 
  16. ^ Kim, M.A.; Ye, Y.M.; Park, J.W.; Lee, J.H.; Lee, S.K.; Kim, C.W.; Jung, K.S.; Kim, J.H.; Yoo, H.S.; Kim, S.H; Shin, Y.S; Nahm, D.H.; Park, H.S. (2013). "A Computerized Asthma-Specific Quality of Life: A Novel Tool for Reflecting Asthma Control and Predicting Exacerbation". International Archives of Allergy and Immunology 163 (1): 36–42. doi:10.1159/000356336. PMID 24247849. Retrieved 25 November 2013. 
  17. ^ Cano Fuentes, G.; Dastis Bendala, C; Morales Barroso, I; Manzanares Torne, M.L.; Fernandez Gregorio, A.; Martin Romana, L. (2013). "A randomised clinical trial to evaluate the effectiveness of an educational intervention developed for adult asthmatics in a primary care centre.". Atencion primaria. doi:10.1016/j.aprim.2013.04.005. PMID 24176681. Retrieved 25 November 2013. 
  18. ^ Freitas, D.A.; Holloway, E.A.; Bruno, S.S.; Chaves, G.S.; Fregonezi, G.A.; Mendonca, K.M. (2013). "Breathing exercises for adults with asthma.". The Cochrane database of systematic reviews 1 (10). doi:10.1002/14651858.CD001277.pub3. 
  19. ^ Meads, David M.; McKenna, Stephen P.; Doward, Lynda C.; Pokrzywinski, Robin; Revicki, Dennis; Hunter, Cameron; Glendenning, G. Alastair (2010). "Development and validation of the Asthma Life Impact Scale (ALIS)". Respiratory Medicine 104 (5): 633–43. doi:10.1016/j.rmed.2009.11.023. PMID 20053543. 
  20. ^ Crawford, SR. "Further Developments of the Asthma Life Impact Scale (ALIS)". Galen-Research.com. Galen Research. Retrieved 14 October 2013. 
  21. ^ Arnold, RJG; Zhou, Y; Wong, KS; Sung, J (2005). "Psk8 Impact of Atopic Dermatitis on the Quality-Of-Life of Parents of Children with Atopic Dermatitis". Value in Health 8 (3): 332. doi:10.1016/S1098-3015(10)62872-0. 
  22. ^ McKenna, Stephen P.; Whalley, Diane; Dewar, Abigail L.; Erdman, Ruud A. M.; Kohlmann, Thomas; Niero, Mauro; Baró, Eva; Cook, Sharon A.; Crickx, Beatrice; Frech, Feride; Van Assche, Daniel van (2005). "International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD)". Quality of Life Research 14 (1): 231–41. doi:10.1007/s11136-004-4231-z. PMID 15789957. 
  23. ^ McKenna, SP; Whalley, D; De Prost, Y; Staab, D; Huels, J; Paul, CF; Van Assche, D (2006). "Treatment of paediatric atopic dermatitis with pimecrolimus (ElidelR, SDZ ASM 981): Impact on quality of life and health-related quality of life". Journal of the European Academy of Dermatology and Venereology 20 (3): 248–54. doi:10.1111/j.1468-3083.2006.01383.x. PMID 16503881. 
  24. ^ Wahn, U.; Bos, J. D.; Goodfield, M.; Caputo, R.; Papp, K.; Manjra, A.; Dobozy, A.; Paul, C.; Molloy, S.; Hultsch, T.; Graeber, M.; Cherill, R.; De Prost, Y.; Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group (2002). "Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children". Pediatrics 110 (1 Pt 1): e2. doi:10.1542/peds.110.1.e2. PMID 12093983. 
  25. ^ Kapp, Alexander; Papp, Kim; Bingham, Ann; Fölster-Holst, Regina; Ortonne, Jean-Paul; Potter, Paul C.; Gulliver, Wayne; Paul, Carle; Molloy, Stephen; Barbier, Nathalie; Thurston, Mark; De Prost, Yves; Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group (2002). "Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug". Journal of Allergy and Clinical Immunology 110 (2): 277–84. doi:10.1067/mai.2002.126500. PMID 12170269. 
  26. ^ Rajmil, Luis; Roizen, Mariana; Psy, Alfonso Urzúa; Hidalgo-Rasmussen, Carlos; Fernández, Gabriela; Dapueto, Juan José; Working Group on HRQOL in Children in Ibero-American Countries (2012). "Health-Related Quality of Life Measurement in Children and Adolescents in Ibero-American Countries, 2000 to 2010". Value in Health 15 (2): 312–22. doi:10.1016/j.jval.2011.11.028. PMID 22433763. 
  27. ^ Meads, DM; McKenna, SP; Doward, LC; Hampson, N; McGeown, C (2005). "Psk6 Interpreting Scores on the Quality of Life Index for Atopic Dermatitis (Qoliad)". Value in Health 8 (3): 331. doi:10.1016/S1098-3015(10)62870-7. 
  28. ^ Ehlken, B; Kugland, B; Schramm, B; Quednau, K; Berger, K (2003). "Psn12 Quality-Of-Life in Patients Suffering from Atopic Dermatitis in Germany". Value in Health 6 (6): 787. doi:10.1016/S1098-3015(10)62005-0. 
  29. ^ Lambert, J.; Bostoen, J.; Geusens, B.; Bourgois, J.; Boone, J.; De Smedt, D.; Annemans, L. (2010). "A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results". Archives of Dermatological Research 303 (1): 57–63. doi:10.1007/s00403-010-1082-z. PMID 20842368. 
  30. ^ Bostoen, J.; Bracke, S.; De Keyser, S.; Lambert, J. (2012). "An educational programme for patients with psoriasis and atopic dermatitis: A prospective randomized controlled trial". British Journal of Dermatology 167 (5): 1025–31. doi:10.1111/j.1365-2133.2012.11113.x. PMID 22709422. 
  31. ^ Moed, Heleen; Yang, Quan; Oranje, Arnold P; Panda, Saumya; Van Der Wouden, Johannes C (2012). "Different strategies for using topical corticosteroids for established eczema". In Moed, Heleen. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD010080. 
  32. ^ Lecomte, P; Lambert, J; Degreef, H; Lesaffre, E; De Backer, M (2006). "Psk6 Belgian Drug Utilisation Study of Elidel® in Routine Practice in Atopic Dermatitis". Value in Health 9 (6): A268. doi:10.1016/S1098-3015(10)63408-0. 
  33. ^ Dawson, J; Fitzpatrick, R; Murray, D; Carr, A (1998). "Questionnaire on the perceptions of patients about total knee replacement". The Journal of bone and joint surgery. British volume 80 (1): 63–9. doi:10.1302/0301-620X.80B1.7859. PMID 9460955. 
  34. ^ Xie, Feng; Ye, Hua; Zhang, Yu; Liu, Xia; Lei, Ting; Li, Shu-Chuen (2011). "Extension from inpatients to outpatients: Validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis". International Journal of Rheumatic Diseases 14 (2): 206–10. doi:10.1111/j.1756-185X.2010.01580.x. PMID 21518321. 
  35. ^ McKenna, SP; Hunt, SM (1994). "A measure of family disruption for use in chickenpox and other childhood illnesses". Social science & medicine (1982) 38 (5): 725–31. doi:10.1016/0277-9536(94)90463-4. PMID 8171351. 
  36. ^ Mast, T Christopher; Demuro-Mercon, Carla; Kelly, Claudia M; Floyd, Leigh; Walter, Emmanuel B (2009). "The impact of rotavirus gastroenteritis on the family". BMC Pediatrics 9: 11. doi:10.1186/1471-2431-9-11. PMC 2649068. PMID 19200366. 
  37. ^ Weldam, Saskia W.M.; Schuurmans, Marieke J.; Liu, Rani; Lammers, Jan-Willem J. (2013). "Evaluation of Quality of Life instruments for use in COPD care and research: A systematic review". International Journal of Nursing Studies 50 (5): 688–707. doi:10.1016/j.ijnurstu.2012.07.017. PMID 22921317. 
  38. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 11 October 2013. 
  39. ^ López-Campos, José Luis (2009). "Importancia de la fatiga, calidad del sueño y estado de ánimo en los pacientes con EPOC y la necesidad de disponer de instrumentos para su medición" [Importance of fatigue, sleep quality and mood in patients with chronic obstructive pulmonary disease and the need for measurement instruments]. Archivos de Bronconeumología (in Spansih) 45: 2–6. doi:10.1016/S0300-2896(09)72948-5. PMID 20116755. 
  40. ^ Amir, Marianne; Lewin-Epstein, Noah; Becker, Gideon; Buskila, Dan (2002). "Psychometric Properties of the SF-12 (Hebrew Version) in a Primary Care Population in Israel". Medical Care 40 (10): 918–28. doi:10.1097/00005650-200210000-00009. PMID 12395025. 
  41. ^ McKenna, Stephen P.; Hunt, Sonja M. (1992). "A new measure of quality of life in depression: Testing the reliability and construct validity of the QLDS". Health Policy 22 (3): 321–30. doi:10.1016/0168-8510(92)90005-V. PMID 10122731. 
  42. ^ Baca Baldomero, E; Cervera Enguix, S; Grupo De Estudio, Teseo (2003). "Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release". Actas espanolas de psiquiatria 31 (6): 331–8. PMID 14639509. 
  43. ^ Detke, Michael J.; Lu, Yili; Goldstein, David J.; McNamara, Robert K.; Demitrack, Mark A. (2002). "Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression". Journal of Psychiatric Research 36 (6): 383–90. doi:10.1016/S0022-3956(02)00060-2. PMID 12393307. 
  44. ^ Hudson, James I; Perahia, David G; Gilaberte, Inmaculada; Wang, Fujun; Watkin, John G; Detke, Michael J (2007). "Duloxetine in the treatment of major depressive disorder: An open-label study". BMC Psychiatry 7: 43. doi:10.1186/1471-244X-7-43. PMC 2018694. PMID 17725843. 
  45. ^ Kornstein, SG; Wohlreich, MM; Mallinckrodt, CH; Watkin, JG; Stewart, DE (2006). "Duloxetine efficacy for major depressive disorder in male vs. Female patients: Data from 7 randomized, double-blind, placebo-controlled trials". The Journal of clinical psychiatry 67 (5): 761–70. doi:10.4088/JCP.v67n0510. PMID 16841626. 
  46. ^ Dunner, DL; Kwong, WJ; Houser, TL; Richard, NE; Donahue, RM; Khan, ZM (2001). "Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment with Bupropion Sustained Release: A Study in Patients with Major Depression". Primary care companion to the Journal of clinical psychiatry 3 (1): 10–16. doi:10.4088/PCC.v03n0103. PMC 181153. PMID 15014623. 
  47. ^ Vickrey, B.G. (1993). "A procedure for developing a quality-of-life measure for epilepsy surgery patients.". Epilepsia 34 (Suppl. 4): S22–S27. doi:10.1111/j.1528-1157.1993.tb05912.x. PMID 8348900. 
  48. ^ "Epilepsy Surgery Inventory 55 Survey (ESI-55)". RAND.org. RAND Health. Retrieved 27 November 2013. 
  49. ^ Selai, C.E.; Elstner, K; Trimble, M.R. (2000). "Quality of life pre and post epilepsy surgery". Epilepsy Research 38 (1): 67–74. doi:10.1016/s0920-1211(99)00075-3. PMID 10604607. Retrieved 27 November 2013. 
  50. ^ de Conceicao, P.O.; Nascimento, P.P.; Mazetto, L.; Alonso, N.B.; Yacubian, E.M.; de Araujo Filho, G.M. (2013). "Are psychiatric disorders exclusion criteria for video-EEG monitoring and epilepsy surgery in patients with mesial temporal sclerosis?". Epilepsy & Behaviour 27 (2): 310–314. doi:10.1016/j.yebeh.2013.02.014. Retrieved 27 November 2013. 
  51. ^ Monteiro Ede, A.; Osorio Fde, L.; Veriano, A Jr.; Molina, R.S.; Funayama, S.S.; Terra, V.C.; Velasco, T.R.;Guarnieri, R.; Bianchin, M.; Assirati, J.A. Jr.; Sakamoto, A.C.; Hallak, J.E. (2012). "Validation of the Subjective Handicap of Epilepsy (SHE) in Brazilian patients with epilepsy.". Epilepsy & Behaviour 24 (3): 345–351. doi:10.1016/j.yebeh.2012.04.129. Retrieved 27 November 2013. 
  52. ^ Mangione, Carol M.; Lee, Paul P.; Gutierrez, Peter R.; Spritzer, Karen; Berry, Sandra; Hays, Ron D. (2001). "Development of the 25-list-item National Eye Institute Visual Function Questionnaire". Archives of Ophthalmology 119 (7): 1050–1058. doi:10.1001/archopht.119.7.1050. PMID 11448327. Retrieved 26 November 2013. 
  53. ^ Orr, Peggy; Rentz, Anne M.; Margolis, Mary Kay; Revicki, Dennis A.; Dolan, Chantal M.; Colman, Shoshana; Fine, Jennifer T.; Bressler, Neil M. (2011). "Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in Age-Related Macular Degeneration". Investigative Ophthalmology and Visual Science 52 (6): 3354–3359. doi:10.1167/iovs.10-5645. PMID 21282568. Retrieved 26 November 2013. 
  54. ^ Kirwan, Caitriona; Lanigan, Bernadette; O'Keefe, Michael (2012). "Vision-Related Quality of Life Assessment Using the NEI-VFQ-25 in Adolescents and Young Adults With a History of Congenital Cataract". Journal of Pediatric Ophthalmology and Strabismus 49 (1): 26–31. doi:10.3928/01913913-20110517-02. PMID 21598855. Retrieved 26 November 2013. 
  55. ^ Naik, Rupali K.; Gries, Katharine S.; Rentz, Anne M.; Kowalski, Jonathan W.; Revicki, Dennis A. (2013). "Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis". Quality of Life Research 22 (10): 2801–8. doi:10.1007/s11136-013-0412-y. PMID 23645458. Retrieved 26 November 2013. 
  56. ^ Meads, D.; Doward, L.; McKenna, S.; Fisk, J.; Twiss, J.; Eckert, B. (2009). "The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS)". Multiple Sclerosis 15 (10): 1228–38. doi:10.1177/1352458509106714. PMID 19556314. 
  57. ^ Elbers, Roy G.; Rietberg, Marc B.; Van Wegen, Erwin E. H.; Verhoef, John; Kramer, Sharon F.; Terwee, Caroline B.; Kwakkel, Gert (2011). "Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: A systematic review of measurement properties". Quality of Life Research 21 (6): 925–44. doi:10.1007/s11136-011-0009-2. PMC 3389599. PMID 22012025. 
  58. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 20 November 2013. 
  59. ^ Kattan, Michael (2009). Encyclopedia of Medical Decision Making. SAGE Publications. ISBN 978-1-4129-7198-0. 
  60. ^ Kaplan, R. M.; Patterson, T. L.; Kerner, D. N.; Atkinson, J.; Heaton, R. K.; Grant, I. (1997). "The Quality of Well-Being scale in asymptomatic HIV-infected patients. HNRC Group. HIV Neural Behavioral Research Center". Quality of Life Research 6 (6): 507–14. doi:10.1023/A:1018456031659. PMID 9330551. 
  61. ^ Hughes, T. E.; Kaplan, R. M.; Coons, S. J.; Draugalis, J. R.; Johnson, J. A.; Patterson, T. L. (1997). "Construct Validities of the Quality of Well-Being Scale and the MOS-HIV-34 Health Survey for HIV-infected Patients". Medical Decision Making 17 (4): 439–46. doi:10.1177/0272989X9701700409. PMID 9343802. 
  62. ^ Frosch, Dominick L.; Kaplan, Robert M.; Ganiats, Theodore G.; Groessl, Erik J.; Sieber, William J.; Weisman, Michael H. (2004). "Validity of self-administered quality of well-being scale in musculoskeletal disease". Arthritis & Rheumatism 51: 28. doi:10.1002/art.20071. 
  63. ^ Brooks, Richard (1996). "EuroQol: The current state of play". Health Policy 37 (1): 53–72. doi:10.1016/0168-8510(96)00822-6. PMID 10158943. 
  64. ^ "Euroqol EQ-5D (EQ-5D)". PROQOLID.org. Mapi Research Trust. Retrieved 20 November 2013. 
  65. ^ Desroziers, K; Aballéa, S; Maman, K; Nazir, J; Odeyemi, I; Hakimi, Z (2013). "Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder". Health and quality of life outcomes 11 (1): 200. doi:10.1186/1477-7525-11-200. PMID 24246044. 
  66. ^ Bouwmans, Clazien; Kolk, Annemarie; Oppe, Mark; Schawo, Saskia; Stolk, Elly; Agthoven, Michel; Buitelaar, Jan; Roijen, Leonahakkaart (2013). "Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD". The European Journal of Health Economics. doi:10.1007/s10198-013-0540-x. 
  67. ^ Parthan, A.; Kruse, M.; Agodoa, I.; Silverman, S.; Orwoll, E. (2013). "Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective". Bone 59: 105–13. doi:10.1016/j.bone.2013.11.002. PMID 24231131. 
  68. ^ Hunt, Sonja M.; McKenna, S.P.; McEwen, J.; Williams, Jan; Papp, Evelyn (1981). "The Nottingham health profile: Subjective health status and medical consultations". Social Science & Medicine. Part A: Medical Psychology & Medical Sociology 15 (3): 221–9. doi:10.1016/0271-7123(81)90005-5. PMID 6973203. 
  69. ^ Ebrahim, S; Barer, D; Nouri, F (1986). "Use of the Nottingham Health Profile with patients after a stroke". Journal of Epidemiology & Community Health 40 (2): 166–9. doi:10.1136/jech.40.2.166. PMC 1052513. PMID 3746178. 
  70. ^ Hunt, SM; McEwen, J; McKenna, SP (1985). "Measuring health status: A new tool for clinicians and epidemiologists". The Journal of the Royal College of General Practitioners 35 (273): 185–8. PMC 1960139. PMID 3989783. 
  71. ^ Johansen, K. L.; Finkelstein, F. O.; Revicki, D. A.; Evans, C.; Wan, S.; Gitlin, M.; Agodoa, I. L. (2011). "Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients". Nephrology Dialysis Transplantation 27 (6): 2418–25. doi:10.1093/ndt/gfr697. PMID 22187314. 
  72. ^ Behan, Lucy-Ann; Rogers, Bairbre; Hannon, Mark J.; O'Kelly, Patrick; Tormey, William; Smith, Diarmuid; Thompson, Christopher J.; Agha, Amar (2011). "Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients". Clinical Endocrinology 75 (4): 505–13. doi:10.1111/j.1365-2265.2011.04074.x. PMID 21521342. 
  73. ^ Aydemir, G; Tezer, M S; Borman, P; Bodur, H; Unal, A (2006). "Treatment of tinnitus with transcutaneous electrical nerve stimulation improves patients' quality of life". The Journal of Laryngology & Otology 120 (6): 442–5. doi:10.1017/S0022215106000910. PMID 16556347. 
  74. ^ "36-Item Short Form Survey from the RAND Medical Outcomes Study". RAND.org. RAND. Retrieved 20 November 2013. 
  75. ^ Ware, John E.; Sherbourne, Cathy Donald (1992). "The MOS 36-ltem Short-Form Health Survey (SF-36)". Medical Care 30 (6): 473–83. doi:10.1097/00005650-199206000-00002. PMID 1593914. 
  76. ^ Abulhasan, Mohamad; Elshazly, Tarek A.; Eida, Mohamad; Albadry, Ayman (2013). "Giardia intestinalis in patients with nonulcer dyspepsia". Arab Journal of Gastroenterology 14 (3): 126–9. doi:10.1016/j.ajg.2013.08.004. PMID 24206742. 
  77. ^ Cuevas, BT; Hughes, DC; Parma, DL; Treviño-Whitaker, RA; Ghosh, S; Li, R; Ramirez, AG (2013). "Motivation, exercise, and stress in breast cancer survivors". Supportive care in cancer. doi:10.1007/s00520-013-2038-6. PMID 24249424. 
  78. ^ Avidan, Alon; Hays, Ron D.; Diaz, Natalie; Bordelon, Yvette; Thompson, Alexander W.; Vassar, Stefanie D.; Vickrey, Barbara G. (2013). "Associations of Sleep Disturbance Symptoms with Health-Related Quality of Life in Parkinson's Disease". Journal of Neuropsychiatry 25 (4): 319. doi:10.1176/appi.neuropsych.12070175. 
  79. ^ Gilson, BS; Gilson, JS; Bergner, M; Bobbit, RA; Kressel, S; Pollard, WE; Vesselago, M (1975). "The sickness impact profile. Development of an outcome measure of health care". American journal of public health 65 (12): 1304–10. doi:10.2105/AJPH.65.12.1304. PMC 1776251. PMID 1200192. 
  80. ^ Van Straten, A.; De Haan, R. J.; Limburg, M.; Schuling, J.; Bossuyt, P. M.; Van Den Bos, G. A. M. (1997). "A Stroke-Adapted 30-Item Version of the Sickness Impact Profile to Assess Quality of Life (SA-SIP30)". Stroke 28 (11): 2155–61. doi:10.1161/01.STR.28.11.2155. PMID 9368557. 
  81. ^ Prcic, Alden; Aganovic, Damir; Hadziosmanovic, Osman (2013). "Sickness Impact Profile (SIP) Score, a Good Alternative Instrument for Measuring Quality of Life in Patients with Ileal Urinary Diversions". Acta Informatica Medica 21 (3): 160–5. doi:10.5455/aim.2013.21.160-165. PMC 3804474. PMID 24167383. 
  82. ^ Hulsebos, R. G.; Beltman, F. W.; Dos Reis Miranda, D.; Spangenberg, J. F. A. (1991). "Measuring quality of life with the sickness impact profile: A pilot study". Intensive Care Medicine 17 (5): 285–8. doi:10.1007/BF01713939. PMID 1939874. 
  83. ^ Horsman, John; Furlong, William; Feeny, David; Torrance, George (2003). "The Health Utilities Index (HUI): Concepts, measurement properties and applications". Health and Quality of Life Outcomes 1: 54. doi:10.1186/1477-7525-1-54. PMC 293474. PMID 14613568. 
  84. ^ Furlong, WJ; Feeny, DH; Torrance, GW; Barr, RD (2001). "The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies". Annals of medicine 33 (5): 375–84. doi:10.3109/07853890109002092. PMID 11491197. 
  85. ^ Davis, E. M.; Lynd, L. D.; Grubisic, M.; Kopec, J. A.; Sayre, E. C.; Cibere, J.; Esdaile, J.; Marra, C. A. (2013). "Responsiveness of Health State Utility Values in Knee Osteoarthritis". The Journal of Rheumatology 40 (12): 2075–82. doi:10.3899/jrheum.130176. PMID 24187098. 
  86. ^ Harvie, Heidi S.; Shea, Judy A.; Andy, Uduak U.; Propert, Kate; Schwartz, J. Sanford; Arya, Lily A. (2013). "Validity of utility measures for women with urge, stress, and mixed urinary incontinence". American Journal of Obstetrics and Gynecology 210: 85.e1. doi:10.1016/j.ajog.2013.09.025. 
  87. ^ Ebrahim, S.; Parshuram, C. (2013). "Comparison of utility scores from the Visual Analog Scale and Health Utilities Index 3 in children following pediatric intensive care unit admission". Journal of Child Health Care. doi:10.1177/1367493513496909. 
  88. ^ Doward, LC; McKenna, SP; Meads, DM (2003). "Pin41 Development of the Herpes Outbreak Impact Questionnaire (Hoiq)". Value in Health 6 (6): 760. doi:10.1016/S1098-3015(10)61938-9. 
  89. ^ Meads, David M.; McKenna, Stephen P.; Bonney, Mary-Ann; Bloch, Mark T. (2009). "Further Validation and Responsiveness Assessment of the Herpes Outbreak Impact Questionnaire and Herpes Symptom Checklist". Value in Health 12 (2): 397–400. doi:10.1111/j.1524-4733.2008.00450.x. PMID 18783390. 
  90. ^ Doward, Lynda C.; McKenna, Stephen P.; Meads, David M.; Kahler, Kristijan; Frech, Feride (2009). "The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire". Value in Health 12 (1): 139–45. doi:10.1111/j.1524-4733.2008.00424.x. PMID 18647252. 
  91. ^ Twiss, J.; McKenna, S.; Bloch, M.; Bonney, M.A. (2011). "PIN5 Patient and Clinician Perceived Benefit of Early Consumption of Famciclovir for the Treatment of Herpes Outbreaks". Value in Health 14 (7): A266. doi:10.1016/j.jval.2011.08.193. 
  92. ^ Doward, L. C; McKenna, S. P; Kohlmann, T; Niero, M; Patrick, D; Spencer, B; Thorsen, H. (1998). "The international development of the RGHQoL: A quality of life measure for recurrent genital herpes". Quality of Life Research 7 (2): 143–53. doi:10.1023/A:1008857426633. PMID 9523496. 
  93. ^ Bartlett, Brenda L.; Tyring, Stephen K.; Fife, Kenneth; Gnann Jr, John W.; Hadala, Joseph T.; Kianifard, Farid; Berber, Erhan (2008). "Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial". Journal of Clinical Virology 43 (2): 190–5. doi:10.1016/j.jcv.2008.06.004. PMID 18621575. 
  94. ^ Patel, R; Tyring, S; Strand, A; Price, MJ; Grant, DM (1999). "Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection". Sexually transmitted infections 75 (6): 398–402. doi:10.1136/sti.75.6.398. PMC 1758256. PMID 10754944. 
  95. ^ Spencer, B; Leplège, A; Ecosse, E (1999). "Recurrent genital herpes and quality of life in France". Quality of life research 8 (4): 365–71. doi:10.1023/A:1008904227182. PMID 10472169. 
  96. ^ Patel, R; Boselli, F; Cairo, I; Barnett, G; Price, M; Wulf, HC (2001). "Patients' perspectives on the burden of recurrent genital herpes". International journal of STD & AIDS 12 (10): 640–5. doi:10.1258/0956462011923859. PMID 11564330. 
  97. ^ a b Wirén, L.; Whalley, D; McKenna, S; Wilhelmsen, L (2000). "Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: Validation of the measure by Rasch analysis". Clinical Endocrinology 52 (2): 143–52. doi:10.1046/j.1365-2265.2000.00899.x. PMID 10671940. 
  98. ^ Moock, Joern; Friedrich, Nele; Völzke, Henry; Spielhagen, Christin; Nauck, Matthias; Koltowska-Häggström, Maria; Buchfelder, Michael; Wallaschofski, Henri; Kohlmann, Thomas (2011). "Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: Data of the German KIMS cohort". Growth Hormone & IGF Research 21 (5): 272–8. doi:10.1016/j.ghir.2011.07.005. PMID 21865066. 
  99. ^ Gilet, Hélène; Chachuat, Anne; Viala-Danten, Muriel; Auzière, Sébastien; Koltowska-Häggström, Maria (2010). "Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population: Results from a French Panel Study". Value in Health 13 (4): 495–500. doi:10.1111/j.1524-4733.2009.00689.x. PMID 20102556. 
  100. ^ Badia, X.; Lucas, A.; Sanmartí, A.; Roset, M.; Ulied, A. (1998). "One-year follow-up of quality of life in adults with untreated growth hormone deficiency". Clinical Endocrinology 49 (6): 765–71. doi:10.1046/j.1365-2265.1998.00634.x. PMID 10209564. 
  101. ^ Mukherjee, A.; Tolhurst-Cleaver, S.; Ryder, W. D. J.; Smethurst, L.; Shalet, S. M. (2004). "The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy". Journal of Clinical Endocrinology & Metabolism 90 (3): 1542–9. doi:10.1210/jc.2004-0832. PMID 15613427. 
  102. ^ Gutiérrez, Lia P.; Kołtowska-Häggström, Maria; Jönsson, Peter J.; Mattsson, Anders F.; Svensson, Dag; Westberg, Björn; Luger, Anton (2008). "Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database)". Pharmacoepidemiology and Drug Safety 17 (1): 90–102. doi:10.1002/pds.1510. PMID 17957812. 
  103. ^ Hays, R.D.; Kallich, J.D.; Mapes, D.L.; Coons, S.J.; Carter, W.B. (1994). "Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument". Quality of Life Research 3 (5): 329–338. doi:10.1007/BF00451725. PMID 7841967. Retrieved 25 November 2013. 
  104. ^ Fan, W.F.; Zhang, Q.; Luo, L.H.; Niu, J.Y.; Gu, Y. (2013). "Study on the Clinical Significance and Related Factors of Thirst and Xerostomia in Maintenance Hemodialysis Patients". Kidney and Blood Pressure Research 37 (4–5): 464–474. doi:10.1159/000355717) (inactive 2014-02-03). PMID 24247643. Retrieved 25 November 2013. 
  105. ^ Cortes-Sanabria, Laura; Paredes-Cesena, Carlos A.; Herrera-Llamas, Rebeca M.; Cruz-Bueno, Yolanda; Soto-Molina, Herman; Pazarin, Leonardo; Cortes, Margarita; Martinez-Ramirez, Hector R. (2013). "Comparison of Cost-Utility Between Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis". Archives of Medical Research 44 (8): 655–61. doi:10.1016/j.arcmed.2013.10.017. PMID 24211750. Retrieved 25 November 2013. 
  106. ^ Fidan, F.; Alkan, B.M.; Tosun, A.; Altunoglu, A; Ardicoglu, O. (2013). "Quality of life and correlation with musculoskeletal problems, hand disability and depression in patients with hemodialysis". International Journal of Rheumatic Disease: n/a. doi:10.1111/1756-185X.12171. 
  107. ^ Patrick, Donald L.; Hurst, Bryan C.; Hughes, Janette (2000). "Further Development and Testing of the Migraine-Specific Quality of Life (MSQOL) Measure". Headache: the Journal of Head and Face Pain 40 (7): 550. doi:10.1046/j.1526-4610.2000.00086.x. 
  108. ^ Garcia-Monco, JC; Foncea, N; Bilbao, A; Ruiz De Velasco, I; Gomez-Beldarrain, M (2007). "Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients". Cephalalgia 27 (8): 920–8. doi:10.1111/j.1468-2982.2007.01367.x. PMID 17645757. 
  109. ^ Spigt, M.; Weerkamp, N.; Troost, J.; Van Schayck, C. P.; Knottnerus, J. A. (2011). "A randomized trial on the effects of regular water intake in patients with recurrent headaches". Family Practice 29 (4): 370–5. doi:10.1093/fampra/cmr112. PMID 22113647. 
  110. ^ Mérelle, SY; Sorbi, MJ; Van Doornen, LJ; Passchier, J (2008). "Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: Short-term effects of a randomized controlled trial". Cephalalgia 28 (2): 127–38. doi:10.1111/j.1468-2982.2007.01472.x (inactive 2014-02-03). PMID 18197883. 
  111. ^ Doward, L.; McKenna, S.; Meads, D.; Twiss, J; Eckert, B. (2009). "The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)". Multiple Sclerosis 15 (9): 1092–102. doi:10.1177/1352458509106513. PMID 19556315. 
  112. ^ "Poster I". Multiple Sclerosis Journal 18 (4 Suppl): 55. 2012. doi:10.1177/1352458512459019. 
  113. ^ van Lokven, T.; Kempcke, R.; Ziemssen, T.; Meergans, M. (October 20, 2011). "Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)". 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands. Retrieved October 9, 2013. 
  114. ^ Cascione, Mark; Wynn, Daniel; Agashivala, Neetu; McCague, Kevin; Pestreich, Linda; Schofield, Lesley; Kim, Edward; Barbato, Luigi (12/02/2013). "Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod". Neurology 80 (1). Retrieved 9 October 2013. 
  115. ^ Maurer, M.; Ortler, S.; Baier, M.; Meergans, M.; Scherer, P.; Hofmann, W.; Tracik, F. (2012). "Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients". Multiple Sclerosis Journal 19 (5): 631–8. doi:10.1177/1352458512463481. PMID 23069874. 
  116. ^ Keenan, Anne-Maree; McKenna, Stephen P.; Doward, Lynda C.; Conaghan, Philip G.; Emery, Paul; Tennant, Alan (2008). "Development and validation of a needs-based quality of life instrument for osteoarthritis". Arthritis & Rheumatism 59 (6): 841. doi:10.1002/art.23714. 
  117. ^ "Treating painful hand osteoarthritis using low dose oral prednisolone- assessing short-term pain and imaging outcomes". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013. 
  118. ^ "An open label study to assess the effectiveness of oral methotrexate in reducing pain in knee osteoarthritis". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013. 
  119. ^ "HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial". Eu Clinical Trials Register. European Medicines Council. Retrieved 20 November 2013. 
  120. ^ a b De Jong, Z.; Van Der Heijde, D.; McKenna, S. P.; Whalley, D. (1997). "The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific quality of life instrument". Rheumatology 36 (8): 878. doi:10.1093/rheumatology/36.8.878. 
  121. ^ Adams, J.; Chapman, J.; Bradley, S.; Ryan, S. J. (2012). "Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology". Rheumatology 52 (3): 460–4. doi:10.1093/rheumatology/kes296. PMID 23118412. 
  122. ^ Dougados, M.; Kissel, K.; Sheeran, T.; Tak, P. P.; Conaghan, P. G.; Mola, E. M.; Schett, G.; Amital, H.; Navarro-Sarabia, F.; Hou, A.; Bernasconi, C.; Huizinga, T. (2012). "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)". Annals of the Rheumatic Diseases 72 (1): 43–50. doi:10.1136/annrheumdis-2011-201282. PMC 3551223. PMID 22562983. 
  123. ^ "Efficacy of tocilizumab in patients with rheumatoid arthritis". Current Controlled Trials. Springer Science+Business Media. Retrieved 2 October 2013. 
  124. ^ Quinn, Mark A.; Conaghan, Philip G.; O'Connor, Philip J.; Karim, Zunaid; Greenstein, Adam; Brown, Andrew; Brown, Clare; Fraser, Alexander; Jarret, Stephen; Emery, Paul (2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism 52: 27. doi:10.1002/art.20712. 
  125. ^ Bejarano, V.; Conaghan, P. G.; Quinn, M. A.; Saleem, B.; Emery, P. (2010). "Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis". Rheumatology 49 (10): 1971–4. doi:10.1093/rheumatology/keq194. PMID 20595536. 
  126. ^ McKenna, Stephen P; Ratcliffe, Julie; Meads, David M; Brazier, John E (2008). "Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses". Health and Quality of Life Outcomes 6: 65. doi:10.1186/1477-7525-6-65. PMC 2546377. PMID 18718016. 
  127. ^ McKenna, S. P.; Doughty, N.; Meads, D. M.; Doward, L. C.; Pepke-Zaba, J. (2006). "The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension". Quality of Life Research 15 (1): 103–15. doi:10.1007/s11136-005-3513-4. PMID 16411035. 
  128. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013. 
  129. ^ Channick, Richard; Voswinckel; Rubin, Lewis; Vultaggio (2012). "Inhaled treprostinil: A therapeutic review". Drug Design, Development and Therapy: 19. doi:10.2147/DDDT.S19281. 
  130. ^ Chen, Hubert; Rosenzweig, Erika B; Gotzkowsky, S Karl; Arneson, Carl; Nelsen, Andrew C; Bourge, Robert C (2013). "Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension". Health and Quality of Life Outcomes 11: 31. doi:10.1186/1477-7525-11-31. PMC 3610124. PMID 23496856. 
  131. ^ Tay, Edgar L.W.; Papaphylactou, Maria; Diller, Gerhard Paul; Alonso-Gonzalez, Rafael; Inuzuka, Ryo; Giannakoulas, Georgios; Harries, Carl; Wort, Stephen John; Swan, Lorna; Dimopoulos, Konstantinos; Gatzoulis, Michael A. (2011). "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy". International Journal of Cardiology 149 (3): 372–6. doi:10.1016/j.ijcard.2010.02.020. PMID 20304507. 
  132. ^ Suntharalingam, Jay (2008). "Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension". CHEST Journal 134 (2): 229–36. doi:10.1378/chest.07-2681. PMID 18263674. 
  133. ^ McKenna, Stephen P.; Lebwohl, Mark; Kahler, Kristijan N. (2005). "Development of the US PSORIQoL: A psoriasis-specific measure of quality of life". International Journal of Dermatology 44 (6): 462–9. doi:10.1111/j.1365-4632.2005.01941.x. PMID 15941432. 
  134. ^ McKenna, S.P.; Cook, S.A.; Whalley, D.; Doward, L.C.; Richards, H.L.; Griffiths, C.E.M.; Van Assche, D. (2003). "Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials". British Journal of Dermatology 149 (2): 323–31. doi:10.1046/j.1365-2133.2003.05492.x. PMID 12932239. 
  135. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 13 November 2013. 
  136. ^ "Psoriasis: management of psoriasis". NICE.org.uk. National Institute for Health and Care Excellence. Retrieved 13 November 2013. 
  137. ^ "CAEB071C2201". ClinicalTrialsRegister.eu. EU Clinical Trials Register. Retrieved 13 November 2013. 
  138. ^ Brodszky, V; Péntek, M; Bálint, PV; Géher, P; Hajdu, O; Hodinka, L; Horváth, G; Koó, É; Polgár, A; Seszták, M; Szántó, S; Ujfalussy, I; Gulácsi, L (2010). "Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: Results from a cross-sectional survey". Scandinavian Journal of Rheumatology 39 (4): 303–9. doi:10.3109/03009740903468982. PMID 20166848. 
  139. ^ McKenna, S P; Doward, LC; Whalley, D; Tennant, A; Emery, P; Veale, DJ (2004). "Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritis". Annals of the Rheumatic Diseases 63 (2): 162–9. doi:10.1136/ard.2003.006296. PMC 1754880. PMID 14722205. 
  140. ^ Marzo-Ortega, H.; McGonagle, D.; Rhodes, L. A; Tan, A.; Conaghan, P. G; O'Connor, P.; Tanner, S. F; Fraser, A.; Veale, D.; Emery, P. (2007). "Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis". Annals of the Rheumatic Diseases 66 (6): 778–81. doi:10.1136/ard.2006.063818. PMC 1954680. PMID 17185324. 
  141. ^ ClinicalTrials.gov NCT00427362 A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
  142. ^ Brown, Benjamin C.; McKenna, Stephen P.; Solomon, Mattea; Wilburn, Jeanette; McGrouther, Duncan A.; Bayat, Ardeshir (2010). "The Patient-Reported Impact of Scars Measure: Development and Validation". Plastic and Reconstructive Surgery 125 (5): 1439–49. doi:10.1097/PRS.0b013e3181d4fd89. PMID 20440163. 
  143. ^ Wilburn, J; McKenna, SP; Brown, B; Solomon, M; McGrouther, DA; Bayat, A (2009). "Pss36 Development and Validation of the Patient-Reported Impact of Scars Measure (Prism)". Value in Health 12 (7): A459. doi:10.1016/S1098-3015(10)75273-6. 
  144. ^ Doward, L C; McKenna, S P; Whalley, D; Tennant, A; Griffiths, B; Emery, P; Veale, D J (2009). "The development of the L-QoL: A quality-of-life instrument specific to systemic lupus erythematosus". Annals of the Rheumatic Diseases 68 (2): 196–200. doi:10.1136/ard.2007.086009. PMID 18385276. 
  145. ^ Castelino, M.; Abbott, J.; McElhone, K.; Teh, L.-S. (2012). "Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: A review of the literature". Rheumatology 52 (4): 684–96. doi:10.1093/rheumatology/kes370. PMID 23264550. 
  146. ^ Yazdany, Jinoos (2011). "Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire". Arthritis Care & Research 63: S413. doi:10.1002/acr.20636.